Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy.
Viruses. 2021 Mar 8;13(3):432. doi: 10.3390/v13030432.
The availability of all oral direct acting antiviral agents (DAAs) has revolutionized the management of HCV infections in recent years, allowing to achieve a sustained virological response (SVR) in more than 95% of cases, irrespective of hepatitis C Virus (HCV) genotype or staging of liver disease. Although rare, the failure to the latest-generation regimens (grazoprevir/elbasvir, sofosbuvir/velpatasvir, pibrentasvir/glecaprevir) represents a serious clinical problem, since the data available in the literature on the virological characteristics and management of these patients are few. The aim of the present narrative review was to provide an overview of the impact of baseline RASs in patients treated with the latest-generation DAAs and to analyze the efficacy of the available retreatment strategies in those who have failed these regimens.
近年来，所有口服直接作用抗病毒药物（DAA）的出现彻底改变了丙型肝炎病毒（HCV）感染的治疗模式，使得无论 HCV 基因型或肝病分期如何，超过 95%的患者都能实现持续病毒学应答（SVR）。尽管较为罕见，但最新一代方案（格卡瑞韦/哌仑他韦、索磷布韦/维帕他韦、奥比帕利/达塞布韦）的失败仍然是一个严重的临床问题，因为目前文献中关于这些患者病毒学特征和管理的数据较少。本综述旨在概述基线耐药相关突变（RAS）对接受最新一代 DAA 治疗患者的影响，并分析这些方案失败患者可采用的现有补救治疗策略的疗效。
